Clinical bottom line
Cervical insufficiency, characterized by premature cervical dilation leading to preterm birth, remains a significant obstetric challenge. Advances in diagnostic tools and treatment options offer promising strategies to improve pregnancy outcomes. Current evidence supports the use of cervical length screening and progesterone supplementation as effective interventions. However, individualized care based on risk factors and patient history is crucial for optimizing management.
What the evidence shows
Recent studies underscore the importance of cervical length measurement via transvaginal ultrasound as a predictive tool for cervical insufficiency. A systematic review by Romero et al. (2016) highlights that a cervical length of less than 25 mm between 16 and 24 weeks of gestation is associated with an increased risk of preterm birth (PMID: 26761339).
Progesterone supplementation, particularly vaginal progesterone, has been shown to reduce the risk of preterm birth in women with a short cervix. A meta-analysis by Romero et al. (2018) demonstrated that vaginal progesterone reduces the risk of preterm birth before 33 weeks by approximately 42% in women with a singleton pregnancy and a short cervix (PMID: 29502949).
Cerclage, a surgical intervention involving the placement of a stitch around the cervix, is recommended for women with a history of spontaneous preterm birth and a short cervix. The Cervical Stitch Trial (2018) confirmed that cerclage significantly reduces the risk of preterm birth in high-risk women (PMID: 30344075).
Caveats and uncertainty
While cervical length screening and progesterone supplementation are effective, their implementation should be tailored to individual risk profiles. The predictive value of cervical length varies across populations, and not all women with a short cervix will benefit from progesterone. Moreover, cerclage carries risks such as infection and cervical laceration, necessitating careful patient selection.
The heterogeneity of study populations and variations in clinical protocols contribute to uncertainty in the generalizability of findings. Further research is needed to refine risk stratification and to explore the potential role of emerging biomarkers in predicting cervical insufficiency.
How this may change practice
The integration of cervical length screening into routine prenatal care for at-risk populations can facilitate early identification and intervention, potentially reducing preterm birth rates. Progesterone supplementation and cerclage should be considered as part of a comprehensive management plan for women with a history of preterm birth or a diagnosed short cervix.
Clinicians should remain informed about evolving guidelines and emerging evidence to provide personalized care. Collaborative decision-making with patients, considering their preferences and values, is essential in managing cervical insufficiency.